EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Insulin resistance, clinical presentation and resistance to selective serotonin and noradrenaline reuptake inhibitors in major depressive disorder

Anna J Krupa, Adrian A Chrobak, Zbigniew Sołtys, Dominika Dudek, Bernadeta Szewczyk, Marcin Siwek

Pharmacological Reports · 2024

DOI: 10.1007/s43440-024-00621-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacological Reports, 2024. Verfasst von Anna J Krupa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Affective Disorders, Jagiellonian University Medical College, ul. Kopernika 21a, Krakow, 31-501, Poland. Hauptthemen laut MEDLINE: Major Depressive Disorder, Insulin Resistance, Serotonin and Noradrenaline Reuptake Inhibitors. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Uniwersytet Jagielloński Collegium Medicum.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The understanding of mechanisms underlying non-response to antidepressants is limited. The latest data highlights the role of insulin resistance (IR) in major depressive disorder (MDD) pathophysiology, presentation, and treatment efficacy. This work aimed to assess IR in MDD and explore the relationships between IR, MDD presentation and non-response to selective serotonin and noradrenaline reuptake inhibitors (SNRI).

Methods

67 MDD individuals: 36 responsive (MDD T[+]), 31 non-responsive (MDD T[−]) to SNRI and 30 healthy controls were recruited. The treatment response criteria were: Clinical Global Impression Scale-Improvement score of 1 or 2 after ≥ 8 weeks of treatment. Participants were assessed by physician and self-report tools measuring depression, anhedonia, anxiety, bipolarity, sleep quality. Blood samples were collected to assess fasting glucose and insulin levels and calculate HOMA-IR (homeostasis model assessment of insulin resistance).

Results

MDD T[-] vs. MDD T[+] had significantly higher body mass index, insulin levels, and HOMA-IR. MDD T[-] presented higher levels of depressed mood, appetite/weight changes, loss of interest, energy, overall depressive symptoms, and sleep impairment; some evaluations suggested higher anhedonia and anxiety in MDD T[-] vs. MDD T[+]. Insulin and IR were weakly but significantly correlated with the severity of psychomotor symptoms, energy level, thoughts of death/suicide, self-criticism, appetite/weight, depressed mood symptoms, sleep problems. IR was weakly but significantly correlated with anhedonia.

Conclusion

IR appears to be linked to depressive symptoms characteristic of the “metabolic” MDD subtype, such as psychomotor changes, energy level, anhedonia, sleep problems, appetite/weight changes, state and trait anxiety, sleep quality, and non-response to SNRI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderInsulin ResistanceSerotonin and Noradrenaline Reuptake InhibitorsHumansMaleFemaleAdultMiddle AgedAntidepressive AgentsSelective Serotonin Reuptake InhibitorsInsulinBlood GlucoseCase-Control StudiesAnxiety

Stichwörter der Autor:innen

Depression subtypeInsulinInsulin resistanceMajor depressive disorder (MDD)Metabolic depressionSelective serotonin and noradrenaline reuptake inhibitors (SNRI)

Substanzen

Serotonin and Noradrenaline Reuptake InhibitorsAntidepressive AgentsSelective Serotonin Reuptake InhibitorsInsulinBlood Glucose

Autor:innen und Institutionen

  • Department of Affective Disorders, Jagiellonian University Medical College, ul. Kopernika 21a, Krakow, 31-501, Poland.
  • Department of Adult Psychiatry, Jagiellonian University Medical College, Kopernika 21a, Krakow, 31-501, Poland.
  • Institute of Zoology and Biomedical Research, Laboratory of Experimental Neuropathology, Jagiellonian University, Gronostajowa 9, Krakow, 30-387, Poland.
  • Department of Neurobiology, Maj Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, Krakow, 31-343, Poland.
  • Department of Affective Disorders, Jagiellonian University Medical College, ul. Kopernika 21a, Krakow, 31-501, Poland. marcin.siwek@uj.edu.pl.

Förderung

  • Uniwersytet Jagielloński Collegium Medicum

Zitieren

APA

Krupa, A. J., Chrobak, A. A., Sołtys, Z., Dudek, D., Szewczyk, B., & Siwek, M. (2024). Insulin resistance, clinical presentation and resistance to selective serotonin and noradrenaline reuptake inhibitors in major depressive disorder. Pharmacological Reports. https://doi.org/10.1007/s43440-024-00621-5

Vancouver

Krupa AJ, Chrobak AA, Sołtys Z, Dudek D, Szewczyk B, Siwek M. Insulin resistance, clinical presentation and resistance to selective serotonin and noradrenaline reuptake inhibitors in major depressive disorder. Pharmacological Reports. 2024. doi:10.1007/s43440-024-00621-5

BibTeX
@article{Krupa2024,
  author = {Krupa, Anna J and Chrobak, Adrian A and Sołtys, Zbigniew and Dudek, Dominika and Szewczyk, Bernadeta and Siwek, Marcin},
  title = {Insulin resistance, clinical presentation and resistance to selective serotonin and noradrenaline reuptake inhibitors in major depressive disorder},
  journal = {Pharmacological Reports},
  year = {2024},
  doi = {10.1007/s43440-024-00621-5}
}
Kostenlos starten →